Almirall SA License Agreement of lebrikizumab for Atopic Dermatitis in Europe Conference Call Transcript
Good day and welcome to the Almirall webcast. Today's conference is being recorded.
At this time, I would like to turn the conference over to Pablo Divasson. Please go ahead, sir.
Thank you, Annette. Good afternoon, everyone. We're pleased to update you today on the lebrikizumab option. The presentation was released today and is available on our corporate website.
Presenting today, we have Peter Guenter, Chief Executive Officer; and Bhushan Hardas, Executive Vice President, Research and Development, CSO. David Nieto, Executive Vice President and CFO, is also going to be available during the Q&A.
Before we move ahead, I would like to remind you that certain statements that we will make in this presentation are forward-looking statements. The forward-looking statements reflect Almirall's judgment and analysis only as of today, and results may differ materially from current expectations based on a number of factors affecting our businesses
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
